来自MSN12 个月
Sanofi to Buy Inhibrx for $2.2 Billion in Rare-Disease Push
The California biotech’s founder and CEO, Mark Lappe, will run a spinoff with the rest of the research and the employees that Sanofi will help capitalize, the companies said. Sanofi is acquiring ...
来自MSN12 个月
Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of ...
Following the acquisition, New Inhibrx will continue to operate under the “Inhibrx” name, with Mark Lappe as Chairman and CEO. Sanofi will also retire Inhibrx’s outstanding third-party debts ...